Novartis' skin disease drug gets US FDA approval

(Reuters) -The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday. The twice-daily pill, Rhapsido, is approved for patients who have symptoms of chronic spontaneous urticaria (CSU) despite standard therapies. CSU is a long-term skin condition without a known cause, characterized by